* Metacrine Inc MTCR.OQ MTCR.O is expected to show no
change
in quarterly revenue when it reports results on November 9
(estimated).
*
* Refinitiv's mean analyst estimate for Metacrine Inc is
for a
loss of 10 cents per share.
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Metacrine
Inc is
$0.5, above its last closing price of $0.39.
This summary was machine generated November 7 at 19:33 GMT. All
figures in US dollars unless otherwise stated